199 related articles for article (PubMed ID: 33579226)
21. Comprehensive Molecular Profiling of Intrahepatic and Extrahepatic Cholangiocarcinomas: Potential Targets for Intervention.
Lowery MA; Ptashkin R; Jordan E; Berger MF; Zehir A; Capanu M; Kemeny NE; O'Reilly EM; El-Dika I; Jarnagin WR; Harding JJ; D'Angelica MI; Cercek A; Hechtman JF; Solit DB; Schultz N; Hyman DM; Klimstra DS; Saltz LB; Abou-Alfa GK
Clin Cancer Res; 2018 Sep; 24(17):4154-4161. PubMed ID: 29848569
[No Abstract] [Full Text] [Related]
22. Molecular classification and therapeutic targets in extrahepatic cholangiocarcinoma.
Montal R; Sia D; Montironi C; Leow WQ; Esteban-Fabró R; Pinyol R; Torres-Martin M; Bassaganyas L; Moeini A; Peix J; Cabellos L; Maeda M; Villacorta-Martin C; Tabrizian P; Rodriguez-Carunchio L; Castellano G; Sempoux C; Minguez B; Pawlik TM; Labgaa I; Roberts LR; Sole M; Fiel MI; Thung S; Fuster J; Roayaie S; Villanueva A; Schwartz M; Llovet JM
J Hepatol; 2020 Aug; 73(2):315-327. PubMed ID: 32173382
[TBL] [Abstract][Full Text] [Related]
23. Molecular profiling of cholangiocarcinoma shows potential for targeted therapy treatment decisions.
Voss JS; Holtegaard LM; Kerr SE; Fritcher EG; Roberts LR; Gores GJ; Zhang J; Highsmith WE; Halling KC; Kipp BR
Hum Pathol; 2013 Jul; 44(7):1216-22. PubMed ID: 23391413
[TBL] [Abstract][Full Text] [Related]
24. Circulating oncometabolite 2-hydroxyglutarate is a potential surrogate biomarker in patients with isocitrate dehydrogenase-mutant intrahepatic cholangiocarcinoma.
Borger DR; Goyal L; Yau T; Poon RT; Ancukiewicz M; Deshpande V; Christiani DC; Liebman HM; Yang H; Kim H; Yen K; Faris JE; Iafrate AJ; Kwak EL; Clark JW; Allen JN; Blaszkowsky LS; Murphy JE; Saha SK; Hong TS; Wo JY; Ferrone CR; Tanabe KK; Bardeesy N; Straley KS; Agresta S; Schenkein DP; Ellisen LW; Ryan DP; Zhu AX
Clin Cancer Res; 2014 Apr; 20(7):1884-90. PubMed ID: 24478380
[TBL] [Abstract][Full Text] [Related]
25. Intratumoral heterogeneity of intrahepatic cholangiocarcinoma.
Walter D; Döring C; Feldhahn M; Battke F; Hartmann S; Winkelmann R; Schneider M; Bankov K; Schnitzbauer A; Zeuzem S; Hansmann ML; Peveling-Oberhag J
Oncotarget; 2017 Feb; 8(9):14957-14968. PubMed ID: 28146430
[TBL] [Abstract][Full Text] [Related]
26. Current challenges to underpinning the genetic basis for cholangiocarcinoma.
Cigliano A; Chen X; Calvisi DF
Expert Rev Gastroenterol Hepatol; 2021 May; 15(5):511-526. PubMed ID: 33888034
[TBL] [Abstract][Full Text] [Related]
27. Cholangiolocellular Carcinoma With "Ductal Plate Malformation" Pattern May Be Characterized by ARID1A Genetic Alterations.
Sasaki M; Sato Y; Nakanuma Y
Am J Surg Pathol; 2019 Mar; 43(3):352-360. PubMed ID: 30520820
[TBL] [Abstract][Full Text] [Related]
28. Characteristics of genomic alterations in Chinese cholangiocarcinoma patients.
Jiang G; Zhang W; Wang T; Ding S; Shi X; Zhang S; Shi W; Liu A; Zheng S
Jpn J Clin Oncol; 2020 Sep; 50(10):1117-1125. PubMed ID: 32533190
[TBL] [Abstract][Full Text] [Related]
29. Immunohistochemical and molecular features of cholangiolocellular carcinoma are similar to well-differentiated intrahepatic cholangiocarcinoma.
Balitzer D; Joseph NM; Ferrell L; Shafizadeh N; Jain D; Zhang X; Yeh M; di Tommaso L; Kakar S
Mod Pathol; 2019 Oct; 32(10):1486-1494. PubMed ID: 31186529
[TBL] [Abstract][Full Text] [Related]
30. ESMO Scale for Clinical Actionability of Molecular Targets Driving Targeted Treatment in Patients with Cholangiocarcinoma.
Verdaguer H; Saurí T; Acosta DA; Guardiola M; Sierra A; Hernando J; Nuciforo P; Miquel JM; Molero C; Peiró S; Serra-Camprubí Q; Villacampa G; Aguilar S; Vivancos A; Tabernero J; Dienstmann R; Macarulla T
Clin Cancer Res; 2022 Apr; 28(8):1662-1671. PubMed ID: 35042699
[TBL] [Abstract][Full Text] [Related]
31. Target molecular treatment markers in Intrahepatic Cholangiocarcinoma based on Chinese population.
Pu X; Zhu L; Li F; Zheng J; Wu H; Fu Y; Chen J; Qi L
Pathol Res Pract; 2020 Sep; 216(9):153116. PubMed ID: 32825971
[TBL] [Abstract][Full Text] [Related]
32. Cholangiocarcinoma.
Krasinskas AM
Surg Pathol Clin; 2018 Jun; 11(2):403-429. PubMed ID: 29751883
[TBL] [Abstract][Full Text] [Related]
33. Genomic profiling of multifocal intrahepatic cholangiocarcinoma reveals intraindividual concordance of genetic alterations.
Lee SH; Simoneau EB; Karpinets T; Futreal PA; Zhang J; Javle M; Zhang J; Vauthey JN; Lee JS; Estrella JS; Chun YS
Carcinogenesis; 2021 Apr; 42(3):436-441. PubMed ID: 33200197
[TBL] [Abstract][Full Text] [Related]
34. Pan-tumor landscape of fibroblast growth factor receptor 1-4 genomic alterations.
Murugesan K; Necchi A; Burn TC; Gjoerup O; Greenstein R; Krook M; López JA; Montesion M; Nimeiri H; Parikh AR; Roychowdhury S; Schwemmers S; Silverman IM; Vogel A
ESMO Open; 2022 Dec; 7(6):100641. PubMed ID: 36462464
[TBL] [Abstract][Full Text] [Related]
35. Biliary cancer: Utility of next-generation sequencing for clinical management.
Javle M; Bekaii-Saab T; Jain A; Wang Y; Kelley RK; Wang K; Kang HC; Catenacci D; Ali S; Krishnan S; Ahn D; Bocobo AG; Zuo M; Kaseb A; Miller V; Stephens PJ; Meric-Bernstam F; Shroff R; Ross J
Cancer; 2016 Dec; 122(24):3838-3847. PubMed ID: 27622582
[TBL] [Abstract][Full Text] [Related]
36. High Beclin-1 and ARID1A expression corelates with poor survival and high recurrence in intrahepatic cholangiocarcinoma: a histopathological retrospective study.
Bi C; Liu M; Rong W; Wu F; Zhang Y; Lin S; Liu Y; Wu J; Wang L
BMC Cancer; 2019 Mar; 19(1):213. PubMed ID: 30849962
[TBL] [Abstract][Full Text] [Related]
37. Genomic and transcriptional alterations of cholangiocarcinoma.
Ito T; Sakurai-Yageta M; Goto A; Pairojkul C; Yongvanit P; Murakami Y
J Hepatobiliary Pancreat Sci; 2014 Jun; 21(6):380-7. PubMed ID: 24532422
[TBL] [Abstract][Full Text] [Related]
38. Morphological subclassification of intrahepatic cholangiocarcinoma: etiological, clinicopathological, and molecular features.
Liau JY; Tsai JH; Yuan RH; Chang CN; Lee HJ; Jeng YM
Mod Pathol; 2014 Aug; 27(8):1163-73. PubMed ID: 24406866
[TBL] [Abstract][Full Text] [Related]
39. Intrahepatic cholangiocarcinomas with IDH1/2 mutation-associated hypermethylation at selective genes and their clinicopathological features.
Lee K; Song YS; Shin Y; Wen X; Kim Y; Cho NY; Bae JM; Kang GH
Sci Rep; 2020 Sep; 10(1):15820. PubMed ID: 32978444
[TBL] [Abstract][Full Text] [Related]
40. Comprehensive analysis of genomic alterations of Chinese hilar cholangiocarcinoma patients.
Feng F; Wu X; Shi X; Gao Q; Wu Y; Yu Y; Cheng Q; Li B; Yi B; Liu C; Hao Q; Zhang L; Gao C; Jiang X
Int J Clin Oncol; 2021 Apr; 26(4):717-727. PubMed ID: 33387086
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]